Antiviral effect of α-glucosidase inhibitors on viral morphogenesis and binding properties of hepatitis C virus-like particles

Journal of General Virology

Volumn 87, Issue 4, 2006, Pages 861-871

  Chapel, Cynthia ^a   Garcia, Céline ^a   Roingeard, Philippe ^b   Zitzmann, Nicole ^c   Dubuisson, Jean ^d   Dwek, Raymond A ^c   Trépo, Christian ^a   Zoulim, Fabien ^a   Durantel, David ^a  

^a INSERM   (France)

^b UNIVERSITÉ DE TOURS   (France)

^c UNIVERSITY OF OXFORD   (United Kingdom)

^d INSTITUT DE BIOLOGIE DE LILLE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA GLUCOSIDASE INHIBITOR; ANTIVIRUS AGENT; CALNEXIN; GLYCAN; MIGLUSTAT; N BUTYLNONYLDEOXYNOJIRIMYCIN; N NONYLDEOXYGALACTONOJIRIMYCIN; STRUCTURAL PROTEIN; UNCLASSIFIED DRUG; VIRUS GLYCOPROTEIN;

ANIMAL TISSUE; ANTIVIRAL ACTIVITY; ARTICLE; CLINICAL PROTOCOL; CONTROLLED STUDY; DRUG BINDING; DRUG MECHANISM; ENDOPLASMIC RETICULUM; HEPATITIS C; HEPATITIS C VIRUS; HEPATOMA CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN FOLDING; PROTEIN PROTEIN INTERACTION; PROTEIN SYNTHESIS; VIRUS MORPHOGENESIS; VIRUS PARTICLE; VIRUS RESISTANCE;

ALPHA-GLUCOSIDASES; ANIMALS; ANTIVIRAL AGENTS; BACULOVIRIDAE; CELL LINE, TUMOR; CELLS, CULTURED; ENZYME INHIBITORS; GLYCOSYLATION; HEPACIVIRUS; HUMANS; MORPHOGENESIS; SPODOPTERA; VIRAL ENVELOPE PROTEINS; VIRAL STRUCTURAL PROTEINS; VIRION;

ANIMALIA; HEPATITIS C VIRUS;

EID: 33645550893     PISSN: 00221317     EISSN: None     Source Type: Journal    
DOI: 10.1099/vir.0.81503-0     Document Type: Article

References (35)

1. Bartenschlager, R., Frese, M. & Pietschmann, T. (2004). Novel insights into hepatitis C virus replication and persistence. Adv Virus Res 63, 71-180.
2. Baumert, T. F., Ito, S., Wong, D. T. & Liang, T. J. (1998). Hepatitis C virus structural proteins assemble into viruslike particles in insect cells. J Virol 72, 3827-3836.
3. Blissard, G. W. (1996). Baculovirus-insect cell interactions. Cytotechnology 20, 73-93.
4. Braakman, I. & van Anken, E. (2000). Folding of viral envelope glycoproteins in the endoplasmic reticulum. Traffic 1, 533-539.
5. Branza-Nichita, N., Durantel, D., Carrouée-Durantel, S., Dwek, R. A. & Zitzmann, N. (2001). Antiviral effect of N-butyldeoxynojirimycin against bovine viral diarrhea virus correlates with misfolding of E2 envelope proteins and impairment of their association into E1-E2 heterodimers. J Virol 75, 3527-3536.
6. Branza-Nichita, N., Lazar, C, Durantel, D., Dwek, R. A. & Zitzmann, N. (2002). Role of disulfide bond formation in the folding and assembly of the envelope glycoproteins of a pestivirus. Biochem Biophys Res Commun 296, 470-476.
7. Choo, Q.-L., Kuo, G., Weiner, A. J., Overby, L. R., Bradley, D. W. & Houghton, M. (1989). Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 244, 359-362.
8. Choo, Q.-L., Richman, K. H., Han, J. H. & 11 other authors (1991). Genetic organization and diversity of the hepatitis C virus. Proc Natl Acad Sci U S A 88, 2451-2455.
9. Cocquerel, L., Meunier, J.-C., Pillez, A., Wychowski, C. & Dubuisson, J. (1998). A retention signal necessary and sufficient for endoplasmic reticulum localization maps to the transmembrane domain of hepatitis C virus glycoprotein E2. J Virol 72, 2183-2191.
10. Cocquerel, L., Meunier, J. C., Op de Beeck, A., Bonte, D., Wychowski, C. & Dubuisson, J. (2001). Coexpression of hepatitis C virus envelope proteins E1 and E2 in cis improves the stability of membrane insertion of E2. J Gen Virol 82, 1629-1635.
11. Davis, G. L., Albright, J. E., Cook, S. F. & Rosenberg, D. M. (2003). Projecting future complications of chronic hepatitis C in the United States. Liver Transpl 9, 331-338.
12. Dubuisson, J. (2000). Folding, assembly and subcellular localization of hepatitis C virus glycoproteins. Curr Top Microbiol Immunol 242, 135-148.
13. Dubuisson, J., Hsu, H. H., Cheung, R. C., Greenberg, H. B., Russell, D. G. & Rice, C. M. (1994). Formation and intracellular localization of hepatitis C virus envelope glycoprotein complexes expressed by recombinant vaccinia and Sindbis viruses. J Virol 68, 6147-6160.
14. Durantel, D., Branza-Nichita, N., Carrouée-Durantel, S., Butters, T. D., Dwek, R. A. & Zitzmann, N. (2001). Study of the mechanism of antiviral action of iminosugar derivatives against bovine viral diarrhea virus. J Virol 75, 8987-8998.
15. Durantel, D., Carrouée-Durantel, S., Branza-Nichits, N., Dwek, R. A. & Zitzmann, N. (2004). Effects of interferon, ribavirin, and imino-sugar derivatives on cells persistently infected with noncytopathic bovine viral diarrhea virus. Antimicrob Agents Chemother 48, 497-504.
16. Dwek, R. A., Butters, T. D., Platt, F. M. & Zitzmann, N. (2002). Targeting glycosylation as a therapeutic approach. Nat Rev Drug Discov 1, 65-75.
17. Foster, G. R. (2004). Past, present, and future hepatitis C treatments. Semin Liver Dis 24 (Suppl. 2), 97-104.
18. Fried, M. W., Shiffman, M. L., Reddy, K. R. & 11 other authors (2002). Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 347, 975-982.
19. Fung, S. K. & Lok, A. S. (2004). Management of hepatitis B patients with antiviral resistance. Antivir Ther 9, 1013-1026.
20. Helenius, A. & Aebi, M. (2004). Roles of N-linked glycans in the endoplasmic reticulum. Annu Rev Biochem 73, 1019-1049.
21. Johnson, V. A., Brun-Vézinet, F., Clotet, B., Conway, B., Kuritzkes, D. R., Pillay, D., Schapiro, J., Telenti, A. & Richman, D. (2005). Update of the drug resistance mutations in HIV-1: 2005. Top HIV Med 13, 51-57.
22. King, L. A. & Possee, R. D. (1992). The Baculovirus Expression System: a Laboratory Guide, p. 229. London: Chapman & Hall.
23. Liang, T. J. & Heller, T. (2004). Pathogenesis of hepatitis C-associated hepatocellular carcinoma. Gastroenterology 127, S62-S71.
24. Lindenbach, B. D., Evans, M. J., Syder, A. J. & 8 other authors (2005). Complete replication of hepatitis C virus in cell culture. Science 309, 623-626.
25. Locarnini, S., Hatzakis, A., Heathcote, J., Keeffe, E. B., Liang, T. J., Mutimer, D., Pawlotsky, J. M. & Zoulim, F. (2004). Management of antiviral resistance in patients with chronic hepatitis B. Antivir Ther 9, 679-693.
26. Manns, M. P., McHutchison, J. G., Gordon, S. C. & 7 other authors (2001). Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 358, 958-965.
27. Pawlotsky, J.-M. (2005). Current and future concepts in hepatitis C therapy. Semin Liver Dis 25, 72-83.
28. Poynard, T., Ratziu, V., Benhamou, Y., Opolon, P., Cacoub, P. & Bedossa, P. (2000). Natural history of HCV infection. Baillières Best Pract Res Clin Gastroenterol 14, 211-228.
29. Saunier, B., Triyatni, M., Ullanich, L., Maruvada, P., Yen, P. & Kohn, L. D. (2003). Role of the asialoglycoprotein receptor in binding and entry of hepatitis C virus structural proteins in cultured human hepatocytes. J Virol 77, 546-559.
30. Seeff, L. B. (2002). Natural history of chronic hepatitis C. Hepatology 36, S35-S46.
31. Tellinghuisen, T. L. & Rice, C. M. (2002). Interaction between hepatitis C virus proteins and host cell factors. Curr Opin Microbiol 5, 419-427.
32. Triyatni, M., Saunier, B., Maruvada, P., Davis, A. R., Ullanich, L., Heller, T., Patel, A., Kohn, L. D. & Liang, T. J. (2002). Interaction of hepatitis C virus-like particles and cells: a model system for studying viral binding and entry. J Virol 76, 9335-9344.
33. Wakita, T., Pietschmann, T., Kato, T. & 9 other authors (2005). Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nat Med 11, 791-796.
34. Zhong, J., Gastaminza, P., Chang, G. & 7 other authors (2005). Robust hepatitis C virus infection in vitro. Proc Natl Acad Sci U S A 102, 9294-9299.
35. Zitzmann, N., Mehta, A. S., Carrouée, S., Butters, T. D., Platt, F. M., McCauley, J., Blumberg, B. S., Dwek, R. A. & Block, T. M. (1999). Imino sugars inhibit the formation and secretion of bovine viral diarrhea virus, a pestivirus model of hepatitis C virus: implications for the development of broad spectrum anti-hepatitis virus agents. Proc Natl Acad Sci U S A 96, 11878-11882.